Full-Time

Information Security Analyst

Posted on 10/5/2025

Deadline 12/17/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

St Paul, MN, USA

Hybrid

Category
IT & Security (1)
Requirements
  • Degree in Cyber Security, Management Information Systems, Information Security or equivalent work experience
  • Minimum 2 years prior experience in a Cyber Security
  • In depth knowledge of LogRhythm SIEM platform or other SIEM platforms, which includes configuring and maintaining API integrations and source feeds, alerts and alarms
  • In depth knowledge in Qualys Vulnerability Management System, which includes configuring and maintaining
  • In depth knowledge in Cisco Advanced Malware Protection Anti-Virus software, which includes configuring and maintaining
  • Knowledge of ISO/IEC 27001 standards
  • Strong technical acumen with a solid understanding of security technologies and network architecture
  • Strong verbal and written communication skills
  • Independent driver of self-development and continuous learning
  • Knowledge of information security technology, design, research techniques, administration, operating standards, and quality control methods
  • Basic understanding of LAN/WAN technologies and protocols, FTP, Active Directory, VPN technologies (MPLS, IPSEC, etc.), IIS and other network services
  • Experience in a large, formal vulnerability program
  • General knowledge of cloud, wireless network and mobile security
  • Team-oriented and skilled in working within a collaborative environment
Responsibilities
  • Investigates and analyzes security events to evaluate risk, prioritizing findings based on internal and external information
  • Configures and maintains SIEM platform, including areas such as source feeds, alerts, alarms, and API integrations
  • Configures and maintains EDR/antivirus
  • Configures and maintains vulnerability management platform, including areas such as vulnerability scanning, remediation, and mitigation as well as impact and risk analysis
  • Communicates security concerns to the business stakeholders to collectively develop and execute an appropriate remediation/mitigation plan
  • Interacts with security risk and compliance group, adjacent IT departments, and business units as needed to ensure compliance with IT Security goals and policies
  • When needed, assists in administration of other security tools (Data Loss Prevention, Email Security/Spam Filter, End User Training, Mobile Device Management)
  • Maintains up-to-date knowledge of the IT security industry including awareness of new or revised security solutions, improved security processes and evolving attacks and threat vectors
  • Ability to work in a team environment and independently as required
  • Contributes to project planning and scheduling
  • Normally receives minimal instructions on routine work and detailed instructions on new assignments
  • Participate in Architecture design reviews and other technical governance forums across the organization representing the security team across multiple projects
  • Be on call and available after business hours, would require working Holidays and weekends if major security incident occurs
  • Establish and maintain pertinent policies, standards, and procedures
  • Perform duties in compliance with applicable regulations and standards such as Sarbanes Oxley Act, FDA Quality System, and ISO (International Organization for Standardization)
  • Works on routine assignments per written procedures, where ability to recognize deviation from accepted practice is required
  • Contributes to the overall operations and to the achievement of departmental goals
  • Perform job specific tasks in compliance with applicable Regulations, International Standards, and WuXi AppTec Policies and Standard Operating Procedures
  • Understanding of Good Laboratory Practices and Good Manufacturing Practices
  • Other duties as assigned

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surged 28.8% to RMB 12.44 billion with 72% adjusted profit growth.
  • $510 million Delaware facility occupies 1.74 million sq ft by August 2026.
  • Ninth Frost & Sullivan CRDMO Company of the Year Award in 2025 affirms leadership.

What critics are saying

  • BIOSECURE Act bans US federal contracts from 2026, cutting 62% US revenue.
  • PLA-linked genetic testing triggers US blacklisting and client exodus like Pfizer.
  • Lonza undercuts pricing, eroding WuXi Chemistry's 43.7% Q1 2026 growth.

What makes WuXi AppTec unique

  • WuXi AppTec's end-to-end CRDMO platform spans discovery to commercialization across small molecules and biologics.
  • Global network of 20 sites serves 6,000 customers in 30+ countries from Asia, US, and Europe.
  • Open-access model founded in 2000 lowers R&D barriers for pharma and biotech innovators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
WuXi AppTec reports record $6.2B revenue, 41.3% profit surge in 2025

WuXi AppTec, a global pharmaceutical contract research, development and manufacturing organisation, reported record 2025 results, beating full-year guidance. Total revenue reached RMB 45.46 billion, up 15.8% year-on-year, whilst revenue from continuing operations rose 21.4% to RMB 43.42 billion. Adjusted non-IFRS net profit increased 41.3% to RMB 14.96 billion, with the profit margin rising 5.9 percentage points to 32.9%. The company's backlog for continuing operations grew 28.8% to RMB 58.00 billion. The firm added 839 new molecules to its small molecule development and manufacturing pipeline in 2025, bringing the total to 3,452. WuXi AppTec achieved its first MSCI AAA and CDP Climate Change A ratings during the year.

EIN Presswire
Dec 17th, 2025
Yale and Princeton-funded Chinese firm buys stake in Shanghai biotech linked to military

A Chinese investment firm funded by Yale and Princeton universities has purchased a stake in WuXi AppTec, a Shanghai biotech company that US lawmakers say operates genetic testing centres in coordination with China's People's Liberation Army. The company has faced accusations of assisting Beijing in identifying Uyghur Muslims in Xinjiang. Last year, American legislators warned about WuXi AppTec's military connections and operations. The investment highlights concerns about elite US institutions indirectly funding Chinese companies with military ties through their endowment investments. Neither the investment firm nor the universities have publicly commented on the transaction or its implications for national security.

PR Newswire
Dec 10th, 2025
D3 Bio raises $108M Series B to advance global Phase III trials for cancer drug elisrasib

D3 Bio, a clinical-stage biotechnology company focused on oncology therapeutics, has raised $108 million in a Series B financing round. The round was backed by IDG Capital and SongQing Capital, with participation from existing investors including WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi. The funding will primarily support D3 Bio's planned global Phase III pivotal programme for elisrasib (D3S-001), its lead asset targeting KRAS G12C-mutant cancers. The trials will evaluate elisrasib as monotherapy and in combination treatments across the United States, China and the European Union to facilitate global regulatory submissions. The proceeds will also advance D3 Bio's pipeline of targeted and immuno-oncology programmes with first-in-class or best-in-class potential.

PR Newswire
Apr 1st, 2025
Wuxi Apptec'S Changzhou And Taixing Api Sites Successfully Pass Fda Inspections

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of RD and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec's unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide

intelligence360
Feb 17th, 2025
Wuxi Apptec To Spend $510 Million To Occupy 1.74 Million Square Feet Of Space In Middletown Delaware.

WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware. WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware.Middletown, Delaware — According to state and local development sources, WuXi AppTec plans to invest $510,000,000.00 to build out 1,740,000 square feet of new space in Middletown. The company plans to occupy the new space in Middletown, on or about August 1, 2026. According to the company website As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of RD and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTecs integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need and to realize the vision that every drug can be made and every disease can be treated.To learn more about WuXi AppTec, visit http://www.wuxiapptec.com/Company Contact:Rick Connell, [email protected]://www.linkedin.com/in/rick-connell/857-413-2800SOURCE: http://www.intelligence360.ioCopyright (c) 2025 SI360 Inc

INACTIVE